For instance, in 2015, Tris Pharma, Inc. received U.S. Food and Drug Administration approval
and launched its Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-
release oral suspension, CIII (DEA Schedule III) in the U.S. market. Tuzistra XR is indicated for
the treatment and relief of cough and symptoms associated with upper respiratory allergies or a
common cold in adults aged 18 years and older.
Report includes chapters which deeply display the following deliverable about industry :
• Codeine Market Research Objective and Assumption
• Codeine Market Purview - Report Description, Executive Summary, and Coherent Opportunity
Map (COM)
• Codeine Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory
Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain
Analysis, Porter’s Analysis, and PEST Analysis
• Global Codeine Market, By Regions
• Codeine Market Competition by Manufacturers including Production, Share, Revenue, Average
Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Codeine Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Codeine Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers
of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Codeine Market Forecast including Production, Consumption, Import and Export Forecast by
Type, Applications and Region.
• Research Findings and Conclusion
Codeine Market Restraint
Stringent regulations in key regions for codeine formulation is expected to be a major factor
restraining growth of the codeine market in the near future. For instance, in February 2018,
The Therapeutic Goods Administration reclassified codeine as prescription only medicine in
Australia, which was previously available as over-the-counter medication. The fact behind this
reclassification was that regular use of medicines containing codeine may lead to its addiction.